Q3 EPS Forecast for NRx Pharmaceuticals Decreased by Analyst

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright lowered their Q3 2026 EPS estimates for shares of NRx Pharmaceuticals in a report issued on Tuesday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.03 for the quarter, down from their prior estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2030 earnings at $6.15 EPS.

Other analysts also recently issued reports about the company. BTIG Research restated a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Wednesday, February 18th. Ascendiant Capital Markets reissued a “buy” rating and issued a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, February 17th. Finally, Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.00.

NRx Pharmaceuticals Trading Down 0.3%

NRx Pharmaceuticals stock opened at $1.80 on Wednesday. The company has a market capitalization of $57.37 million, a price-to-earnings ratio of -0.77 and a beta of 1.97. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84. The stock’s 50 day moving average is $2.12 and its 200-day moving average is $2.51.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several hedge funds have recently bought and sold shares of NRXP. Anson Funds Management LP lifted its holdings in shares of NRx Pharmaceuticals by 50.3% during the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after acquiring an additional 1,018,853 shares during the period. Vanguard Group Inc. raised its position in NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Commonwealth Equity Services LLC bought a new stake in NRx Pharmaceuticals during the fourth quarter worth $994,000. AdvisorShares Investments LLC boosted its holdings in shares of NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after purchasing an additional 78,339 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after purchasing an additional 33,004 shares in the last quarter. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.